君实生物(01877.HK)注射用无菌粉末JS213获药物临床试验批准

阿斯达克财经

2025/02/06

君实生物(01877.HK) 公布，收到国家药品监督管理局通知，AWT020注射用无菌粉末(项目代号︰JS213)的临床试验申请获得批准，同意本品开展单药以及联合其他抗肿瘤治疗在晚期恶性肿瘤患者中的临床试验。JS213是PD-1和白细胞介素-2双功能性抗体融合蛋白，主要用于晚期恶性肿瘤的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-05 16:25。)AASTOCKS...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2509366372"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2509366372\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2509366372?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","is_english":false,"pubTime":"2025-02-06 00:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2509366372","market":"sh","top_or_hot":-1,"title":"君实生物(01877.HK)注射用无菌粉末JS213获药物临床试验批准","media":"阿斯达克财经","content":"<div>\n<p>君实生物(01877.HK) 公布，收到国家药品监督管理局通知，AWT020注射用无菌粉末(项目代号︰JS213)的临床试验申请获得批准，同意本品开展单药以及联合其他抗肿瘤治疗在晚期恶性肿瘤患者中的临床试验。JS213是PD-1和白细胞介素-2双功能性抗体融合蛋白，主要用于晚期恶性肿瘤的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-05 16:25。)AASTOCKS...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1415077/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物(01877.HK)注射用无菌粉末JS213获药物临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物(01877.HK)注射用无菌粉末JS213获药物临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-06 00:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1415077/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>君实生物(01877.HK) 公布，收到国家药品监督管理局通知，AWT020注射用无菌粉末(项目代号︰JS213)的临床试验申请获得批准，同意本品开展单药以及联合其他抗肿瘤治疗在晚期恶性肿瘤患者中的临床试验。JS213是PD-1和白细胞介素-2双功能性抗体融合蛋白，主要用于晚期恶性肿瘤的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-05 16:25。)AASTOCKS...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1415077/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1415077/latest-news/AAFN","article_id":"2509366372","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1415077/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2509366372","pubTimestamp":1738773060,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"君实生物(01877.HK) 公布，收到国家药品监督管理局通知，AWT020注射用无菌粉末(项目代号︰JS213)的临床试验申请获得批准，同意本品开展单药以及联合其他抗肿瘤治疗在晚期恶性肿瘤患者中的临床试验。JS213是PD-1和白细胞介素-2双功能性抗体融合蛋白，主要用于晚期恶性肿瘤的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-05 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","BK1576":"医药外包概念","BK0239":"医药制造","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","03347":"泰格医药","BK1515":"抗疫概念","BK1161":"生物科技","01877":"君实生物"},"translate_title":"Junshi Biotech (01877. HK) sterile powder for injection JS213 was approved for drug clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"03347":1,"01877":1},"content_text":"君实生物(01877.HK) 公布，收到国家药品监督管理局通知，AWT020注射用无菌粉末(项目代号︰JS213)的临床试验申请获得批准，同意本品开展单药以及联合其他抗肿瘤治疗在晚期恶性肿瘤患者中的临床试验。JS213是PD-1和白细胞介素-2双功能性抗体融合蛋白，主要用于晚期恶性肿瘤的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-05 16:25。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}